PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches - sprookjes - yvandenbroek - TriplyDB

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

http://www.wikidata.org/entity/Q37192606

about

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Emerging targeted therapies for melanoma treatment (review)Autophagy and cancer Targeted therapy for hepatocellular carcinoma: novel agents on the horizon Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin.Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.Drugging the PI3 kinome: from chemical tools to drugs in the clinic.Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women.Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells.Molecular mechanisms linking endometriosis under oxidative stress with ovarian tumorigenesis and therapeutic modalities.

P2860

Q26829652-A5E5B5ED-32D4-4E89-9CA6-31ED3877E9D9 Q26829997-1EB3BD26-435A-4CC0-9C2A-456B0B469D2E Q26865957-205D94B9-61A1-4023-94DA-13E226FE1E3B Q27002288-AD5C0B77-CFE2-4B69-9872-5A930A6B852A Q27711042-21BEBCBC-C68F-4EAD-A74B-E0D848DD3411 Q28484572-66C4EA9D-D3E9-4ECC-A8FE-2C9C00FEBC55 Q33439312-713A95C8-619F-40F8-886A-3CD34B0B168A Q33493174-2A54F4F2-A50B-4BBC-BAB4-015C7A9D789E Q33734538-4E58CFDB-F987-4439-AD39-6D8B14ADA15A Q33823577-DE217D37-F5DC-4ED1-B8C7-2AA282C208DC Q33836807-C0DD3297-4D44-48C3-BE48-6A65EE0A503B Q33968053-C69C887C-CD15-41FC-9965-978B04BB2EC4 Q34024558-828EB56A-B355-4AB7-8179-0F692D506918 Q34264934-9C5C1919-D439-4454-B288-53EF75DB6573 Q34539092-E89CCA6F-B96A-4C58-8D80-ED6B80E99574 Q34673900-CDBAF96A-C528-4C67-9413-A3B5690B5BE6 Q34769343-EC94F016-D777-4823-9E74-7A447126E97D Q34966603-2AA96AD4-88E5-409A-9C3E-89A221EDA6A5 Q35556981-D9E96CA6-47C0-42FB-A813-0ECD947CE801 Q35622141-540B8145-747E-478C-8213-9CDA198C92CB Q35640228-D1CAE1D1-3283-4895-AF04-D30C5C9788EC Q35640301-4186AF64-6CDF-4346-BAF8-87E0A0C99C30 Q35653910-E2EBBE9C-C8AB-402A-AFB5-1621F2F3388E Q35679353-30CC14B4-DE53-4B57-8ADC-74AEF27A1A51 Q35729391-18F6FECA-3565-4C67-B3B9-EB1A4746BCB9 Q35815544-C1DFA94E-0449-4E90-8128-181A528DD754 Q36033370-84B896C0-04C1-402D-A88B-D7CFBA3B4F8F Q36103054-171DE4E2-60AD-4E4F-8FB2-364FE6AD37AB Q36371231-DCD5D23B-06E2-4BED-88D7-7AEE5B76B2D5 Q36450457-37356078-262C-4979-A447-52745D6CA167 Q36546319-552920F0-10A9-47A8-8F2A-BA05210F2BF6 Q36722227-CDA73640-F3A7-4355-9EB2-AB314D3524B3 Q36862768-10D23A14-D72B-414A-AF75-6B4794845B7D Q37183710-8A1D3115-1C4F-4C67-95AA-96BF489B0257 Q37192602-10332FEA-94DE-4C4B-973C-305CEDAA4CB5 Q37192611-CEA7951E-C967-4469-AAD6-E9627D0547C0 Q37192616-83E2A65B-0F9D-4FC1-A644-AE457B9C9EAD Q37315483-9B2AD189-B1AA-46D5-BAA0-9D339501B1A4 Q37407102-611DBC27-BCF5-4FFD-8CCD-18CF694CB7ED Q38005210-C7EFB6B1-9047-4B81-8DD3-8691E915C067

P2860

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches

http://www.wikidata.org/entity/Q37192606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PIK3CA mutations in human soli ...... various therapeutic approaches

@en

PIK3CA mutations in human soli ...... arious therapeutic approaches.

@nl

type

label

PIK3CA mutations in human soli ...... various therapeutic approaches

@en

PIK3CA mutations in human soli ...... arious therapeutic approaches.

@nl

prefLabel

PIK3CA mutations in human soli ...... various therapeutic approaches

@en

PIK3CA mutations in human soli ...... arious therapeutic approaches.

@nl

P1433

Q37192606-0B2AF40F-B854-46BC-920B-6ECBDC1B89E6

P1476

Q37192606-CD8BB74B-9BC2-4F18-B936-7C2CBAA7DD9D

P2093

Q37192606-134DDD0A-7C21-4868-B23B-668B1A2EA101

Q37192606-195A22EB-BA6A-41BA-9C3B-AD09857CE897

Q37192606-3B2D3F1E-CE49-408E-BFE9-69FD2D776CC0

Q37192606-9010D6C7-FA38-40CA-9C3E-2B35B9D3AD76

Q37192606-A413C02F-0F05-44D1-9748-ED5CDF0652F3

Q37192606-B6006EE5-6522-4D59-A687-CAA5F217CD4A

Q37192606-EC0AB721-626E-4F65-A9A4-3D60FCEBBF96

Q37192606-FFB42387-9342-4884-BD29-075E9DBAF21B

P2860

Q37192606-02247576-6D3A-4E5F-8CC7-43731B1DD49A

Q37192606-11AE0288-56C9-432E-B72C-3BBFADA9F470

Q37192606-16C4C654-588B-45D2-9B7F-2543A216A0F5

Q37192606-24B53496-E5AF-41FF-9F43-9B0A065899D2

Q37192606-297CAE43-9163-44ED-896D-779F3B627C65

Q37192606-33B72C1E-A604-4916-B846-418374757943

Q37192606-34DCEA56-060C-4A4C-9237-DDFD0EB7F8C9

Q37192606-359458C9-2CE3-40CA-9D81-CE1C64C7F7F2

Q37192606-427FEAF3-43F2-4C18-A179-B91CBB5111E3

Q37192606-4DA96010-D1A0-4ED4-B899-36AC08314711

P304

Q37192606-334F4423-0BD9-444C-9E3D-E26750C2151A

P31

Q37192606-25E7E0DF-8659-474D-919F-A6D29FF3E9F3

P356

Q37192606-38F3A239-F841-432E-8F65-C454F9C29C94

P433

Q37192606-1DB97008-E44C-4A72-9F47-820FDD389A41

P478

Q37192606-D08F4FE8-ACF5-47F0-8D19-EEBCC6547ED2

P50

Q37192606-B7F39005-EE3C-47D8-AAFF-82D8415903EF

P577

Q37192606-984B061E-4021-4A89-9CC3-B5B70152556C

P5875

Q37192606-4674ED88-2BEC-4BC8-9045-BF555B333D6C

P698

Q37192606-D5FC203F-672C-4F15-A0EE-CA792C83E3D0

P932

Q37192606-A3105AC4-A32C-4966-A48D-3B64C150D35C

P356

P1433

P1476

PIK3CA mutations in human soli ...... various therapeutic approaches

@en

P2093

Andrea Cavallaro

http://www.w3.org/2001/XMLSchema#string

Ferdinando Nicoletti

http://www.w3.org/2001/XMLSchema#string

Franca Stivala

http://www.w3.org/2001/XMLSchema#string

Francesco Basile

http://www.w3.org/2001/XMLSchema#string

Giovanni Ligresti

http://www.w3.org/2001/XMLSchema#string

James A McCubrey

http://www.w3.org/2001/XMLSchema#string

Linda S Steelman

http://www.w3.org/2001/XMLSchema#string

Massimo Libra

http://www.w3.org/2001/XMLSchema#string

P2860

PTEN function: how normal cells control it and tumour cells lose it

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

The phosphoinositide 3-kinase pathway

High frequency of mutations of the PIK3CA gene in human cancers

Signaling by distinct classes of phosphoinositide 3-kinases

PTEN: life as a tumor suppressor

P304

1352-1358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.8.9.8255

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Loredana Militello

P577

2009-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24218571

http://www.w3.org/2001/XMLSchema#string

P698

19305151

http://www.w3.org/2001/XMLSchema#string

P932

3781181

http://www.w3.org/2001/XMLSchema#string